Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

FDA approves Pfizer’s Tukysa regimen for metastatic breast cancer | PharmaVoice

Pharma Tech

FDA approves Pfizer’s Tukysa regimen for metastatic breast cancer

Oct 8, 2026, 10:05 AM

Read Full Article → FDA approves Pfizer’s Tukysa regimen for metastatic breast cancer

FDA approves Pfizer’s Tukysa regimen for metastatic breast cancer

Translate article text

Choose a language and wait for the translated text.

The US FDA has approved Pfizer’s Tukysa (tucatinib) along with pertuzumab and trastuzumab as a maintenance therapy for breast cancer.